Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: More than 132,000 cases of the virus have been reported in 123 countries since it emerged in December in the central Chinese city of Wuhan, WHO director-general Tedros Adhanom Ghebreyesus told a virtual news conference. “Europe has now become the epicenter of the pandemic with more reported cases and deaths than the rest of world combined apart from China,” he said in Geneva. Tedros announced that the WHO was launching a coronavirus Solidarity Response Fund. This would to allow people and organizations to contribute to help fund masks, gloves, gowns and goggles for heath workers, as well as diagnostic kits and investment in research and development, including for vaccines. Facebook will match up to $10 million in donations, while Alphabet Inc’s Google will donate $5 million, the WHO and UN Foundation later announced in a joint statement. Social distancing, where people avoid close proximity or touching, is a “tried and tested method” to slow the spread of a virus but “not a panacea” that will stop transmission, the WHO’s top emergency expert Dr. Mike Ryan said. Each country must decide on its own measures to protect its population, he said, adding: “But we’ve also consistently said that blanket travel measures in their own right will do nothing to protect an individual state.”  Detection and isolation of infected people, as well as tracing their contacts and wider testing, must be part of a comprehensive strategy, Ryan said. “As part of an overall comprehensive strategy, there is a place - particularly inside national borders - for potentially restricting movement between zones, as we’ve seen in certain places,” he said. “But there is rarely a justification for blanket bans, unless of course the context and the risk defines that.”  U.S. President Donald Trump has announced sweeping travel restrictions to prevent people from 26 European countries - except for Britain and Ireland - from traveling to the United States in a bid to limit the virus spread. A number of other countries in recent days have announced stepped up border checks, and canceled flights to other countries, in an effort to contain the spread. Trump on Friday declared a national emergency over the fast-spreading coronavirus, opening the door to providing what he said was about $50 billion in federal aid to fight the disease. Claim: Europe is epicenter of coronavirus pandemic: WHO.

Output: Europe has now become the epicenter of a coronavirus pandemic that has claimed 5,000 lives around the world, “a tragic milestone”, the World Health Organization said on Friday.


Input: Consider Input: Paragraph: "The story includes the cost of this test $1,625 and mentions that insurance companies currently don’t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman’s lifetime risk of developing cancer. There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test. Most experts advise against women taking this test, and the American Cancer Society does not promote the test. The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening. Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy). The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. Additionally, peer-reviewed studies need to be done to determine the best course of prevention if a woman chooses to take the test and discovers she is at higher risk of developing breast cancer. Because the story raised appropriate questions about the quality of the evidence, we give this a satisfactory score. The story lists the annual incidence of new breast cancers and mortality rate. The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman’s decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen. Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test–unlike Decode’s chief executive, who is also interviewed, mainly promoting his company’s product. Researchers help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts. The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer  mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review. The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women’s risk. The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test." Claim: Firm says test judges risk for common breast cancers

Output: "The focus of the story is a newly available genetic test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there is concern about the validity of such tests that have not been subjected to external review. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. The story mentions current prevention guidelines for women who are considered higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However,the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. It is not clear how the new genetic test improves on this current practice, as there was no evidence presented. Researchers and clinicians interviewed help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts."


Input: Consider Input: Paragraph: Half of EU states have designated long lists of drugs that cannot be exported during the coronavirus emergency. The lists include medication used to treat COVID-19 patients such as muscle relaxants, painkillers and hydroxychloroquine. “We ask that national governments lift any export ban on medicines. Such restrictions can lead to shortages elsewhere in the EU,” von der Leyen said in a statement. She also called on governments to avoid stockpiling. Bans are usually justified with the need to fulfil national needs, but Europe has so far faced only limited supply problems from the coronavirus crisis. Temporary shortages have been recorded mostly for drugs used to treat critically ill COVID-19 patients, such as anaesthetics, antibiotics and muscle relaxants that allow people to receive breathing support from ventilators. But national lists comprise many more drugs, including some that have wider uses such as the painkiller paracetamol and insulin, used by diabetics. The European Commission on Wednesday adopted new guidance on drugs supplies, which calls on governments to refrain from export bans and from requisitioning medicines. “Whilst it is understandable that countries wish to ensure the availability of essential medicines nationally, export bans are detrimental to the availability of medicines for European patients even when they are legally justifiable,” the non-binding document says. France, Poland, Belgium and the Czech Republic are among the EU countries with the longest lists of drugs which are temporarily banned from export. The bans apply mostly to distributors, which cover a large part of the EU market and provide the biggest share of supplies to pharmacies. The new guidelines also called on states to stop excessive stockpiling, which the Commission said could contribute to supply shortages. It warned the worst effects on supplies from stockpiling emerge when countries compete among themselves. The Commission is setting up an EU reserve of critical medicines and medical gear to address future needs. Claim: EU urges states to lift drug export bans to prevent shortages.


Output: The head of the European Commission, Ursula von der Leyen, on Wednesday urged European Union states to lift export bans on medicines to avoid causing shortages in the bloc as it tackles the coronavirus crisis.